Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Essex Woodlands makes equity investment in Endologix

Executive Summary

Concurrent with Endologix Inc.'s (minimally invasive aortic disorder treatments) acquisition of Nellix Endovascular Inc., Essex Woodlands Health Ventures has made an equity investment of $15mm in Endologix, giving it a 6% stake in the company. Essex, which was a majority shareholder in Nellix and will now contribute two board members to Endologix, has paid $4.73 (a 6% discount) for 3.17mm common shares.
Deal Industry
  • Medical Devices
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies